Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC - CancerNetwork

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC  CancerNetwork

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCL...

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCLC  Cancer Nursing Today

First-Line ALK Therapy Shows Significant Overall Survival Benefit in Advanced NSCLC - Physician's...

First-Line ALK Therapy Shows Significant Overall Survival Benefit in Advanced NSCLC  Physician's Weekly

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small ce...

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node - ScienceD...

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node  ScienceDirect.com

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC - OncLive

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC  OncLive

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for th...

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain  Frontiers

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable...

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC  Oncodaily

Full article: Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational fo...

Full article: Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies  Taylor & Francis Online

Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectini...

Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib  Wiley Online Library

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting  ASCO Daily News

Postoperative Crizotinib Fails in Early Lung Cancer - MedPage Today

Postoperative Crizotinib Fails in Early Lung Cancer  MedPage Today

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC  CancerNetwork

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung ca...

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report  Frontiers

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resist...

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK - ...

Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK  Oncodaily

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC - OncLive

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC  OncLive

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma ...

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib  Frontiers

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC - OncLive

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC  OncLive

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC - Oncod...

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC  Oncodaily

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025 - Cancer Therapy Advisor

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025  Cancer Therapy Advisor

Yvonne Diaz: Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - Onc...

Yvonne Diaz: Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC  Oncodaily

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo - O...

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo  Oncodaily

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in ...

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient  Frontiers

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-...

Greenness assessment and stability-indicating LC method for determination of alectinib using Box-Behnken design, high-resolution mass spectrometric identification, and molecular docking studies of its novel degradation products  ScienceDirect.com

Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer ...

Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies  Taylor & Francis Online

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node - ScienceD...

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node  ScienceDirect.com

Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et a...

Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et al  Oncodaily

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC  Pharmacy Times

FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell ...

Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report  Wiley Online Library

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers - Medscape

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers  Medscape

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-pos...

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management - OncLive

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management  OncLive

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseud...

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis  Frontiers

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC - ...

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC  Oncodaily

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment - CancerNetwork

Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment  CancerNetwork

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Foll...

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up  JACC Journals

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC - CancerNetwork

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC  CancerNetwork

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncol...

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC  Oncology Nursing News

Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials - CUREtoday.com

Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials  CUREtoday.com

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Instit...

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alect...

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alectinib and its related impurity with measurement uncertainty evaluation and whiteness, blueness, and greenness profile assessments  BMC Chemistry

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positi...

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report  Journal of Medical Case Reports

Reshaping Treatment of Resectable NSCLC: Neoadjuvant Advances Take Center Stage at ASCO25 - ASCO ...

Reshaping Treatment of Resectable NSCLC: Neoadjuvant Advances Take Center Stage at ASCO25  ASCO Daily News

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-posit...

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer  Wiley Online Library

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicent...

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study  BMC Medicine

FDA Approves Alectinib for Early-Stage ALK+ NSCLC - CancerNetwork

FDA Approves Alectinib for Early-Stage ALK+ NSCLC  CancerNetwork

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New Engla...

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Alectinib-induced rash unresponsive to desensitization: a case report and literature review - BMC...

Alectinib-induced rash unresponsive to desensitization: a case report and literature review  BMC Pulmonary Medicine

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC - Targeted Oncology

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC  Targeted Oncology

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - CancerNetwork

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  CancerNetwork

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See Lis...

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See List  Medical Dialogues

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy ...

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib  Cancer Therapy Advisor

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell ly...

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial - Fukano - 2020 - Cancer Science  Wiley Online Library

FDA Grants Priority Review to Alectinib for ALK+ NSCLC - CancerNetwork

FDA Grants Priority Review to Alectinib for ALK+ NSCLC  CancerNetwork

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC - Pharmacy Times

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC  Pharmacy Times

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (A...

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)  ACS Publications

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 - Nature

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1  Nature

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK pos...

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)  Frontiers

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Fron...

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports  Frontiers

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - T...

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - Thoracic Cancer  Wiley Online Library

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature

How ALK Alterations Detected at the Time of EGFR TKI Resistance Impact Treatment Decisions for Ad...

How ALK Alterations Detected at the Time of EGFR TKI Resistance Impact Treatment Decisions for Advanced-Stage NSCLC  ASCO Daily News

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable...

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer  Frontiers

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming cl...

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance  ScienceDirect.com

Narjust Florez: Sarah Waliany on mechanisms of resistance to first-line vs. later-line Alectinib ...

Narjust Florez: Sarah Waliany on mechanisms of resistance to first-line vs. later-line Alectinib for ALK and NSCLC  Oncodaily

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy i...

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement  Frontiers

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - OncLive

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC  OncLive

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - MedPage Today

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC  MedPage Today

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a thir...

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion  ScienceDirect.com

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma - Nature

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma  Nature

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Foll...

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up  JACC Journals

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-sma...

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer  Frontiers

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC - CancerNetwork

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC  CancerNetwork

Choosing Between ALK Inhibitors in the Treatment of NSCLC - OncLive

Choosing Between ALK Inhibitors in the Treatment of NSCLC  OncLive

Anthem Biosciences tells Delhi High Court it won't launch products using anti-cancer drug Alectin...

Anthem Biosciences tells Delhi High Court it won't launch products using anti-cancer drug Alectinib  Bar and Bench

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - Oncology News Central

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC  Oncology News Central

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

ASCO 2025 / Promising new targeted therapy in very rare pediatric cancers - Institut Curie - Espa...

ASCO 2025 / Promising new targeted therapy in very rare pediatric cancers  Institut Curie - Espace presse

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the ...

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature  Journal of Medical Case Reports

Alectinib Improves DFS Vs Chemo in ALK+ Non–Small Cell Lung Cancer - CancerNetwork

Alectinib Improves DFS Vs Chemo in ALK+ Non–Small Cell Lung Cancer  CancerNetwork

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anapla...

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report  Journal of Medical Case Reports

Roche wins second FDA label expansion for Alecensa in NSCLC - Pharmaceutical Technology

Roche wins second FDA label expansion for Alecensa in NSCLC  Pharmaceutical Technology

Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinas...

Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report  Baishideng Publishing

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug...

Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on Bioavailability  ScienceDirect.com

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive cr...

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China  Frontiers

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Ad...

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers  Cancer Therapy Advisor

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC - Fro...

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC  Frontiers

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type o...

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer  Roche